Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Moderate Buy” from Analysts

Hologic, Inc. (NASDAQ:HOLX) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $85.60.

Several equities analysts recently issued reports on HOLX shares. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Argus boosted their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Friday, May 3rd. UBS Group lifted their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Finally, Evercore ISI upped their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th.

Hologic Stock Down 1.0 %

HOLX opened at $74.86 on Friday. The business has a 50 day moving average of $76.32 and a 200-day moving average of $73.53. The stock has a market capitalization of $17.47 billion, a price-to-earnings ratio of 38.19, a P/E/G ratio of 2.51 and a beta of 1.01. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic has a 1-year low of $64.02 and a 1-year high of $82.45.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 EPS. As a group, sell-side analysts anticipate that Hologic will post 4.08 earnings per share for the current year.

Insider Transactions at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the period. Victory Capital Management Inc. grew its position in shares of Hologic by 4.5% during the 4th quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock worth $361,183,000 after buying an additional 216,958 shares during the period. Norges Bank bought a new stake in shares of Hologic during the fourth quarter worth approximately $217,529,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after buying an additional 338,212 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Hologic by 117.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquiring an additional 1,168,564 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.